Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gabriel Velilla
Observed names:
G Velilla,
G. Velilla
Institutions:
Research Institute Hospital 12 de Octubre,
Hospital Universitario 12 De Octubre
Observed institutions:
Research Institute Hospital 12 de Octubre,
Hospital Universitario 12 De Octubre
ORCID:
0000-0002-6367-4892
Observed ORCID:
0000-0002-6367-4892
OpenAlex ID:
A5114189767
Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study
2026
·
Oriol Mirallas
, Fiorella Ruiz-Pace
, et al.
·
npj Precision Oncology
·
4
PDF
Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial design.
2024
·
José Manuel Sepulveda
, Manuel Valiente
, et al.
·
Journal of Clinical Oncology
·
4
454P Tetrahydrocannabinol (THC) / cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial
2024
·
J.M. Sepúlveda
, M. Alonso
, et al.
·
Annals of Oncology
·
3
456P Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study
2024
·
M.A. Mazariegos-Rubi
, R. Gironés Sarrió
, et al.
·
Annals of Oncology
·
2
PDF
Patient‐derived surgical samples reveal the cellular and molecular signatures of glioblastoma infiltration in distinct radiological zones
2026
·
Olaya de Dios
, Juan Romero
, et al.
·
Brain Pathology
·
1
Progression‐Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort
2026
·
Jesús Yaringaño
, Oriol Mirallas
, et al.
·
Cancer Medicine
·
1
Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Preliminary results of phase Ib/II CAN-201 NDG trial.
2025
·
Juan Manuel Sepulveda
, Manuel Valiente
, et al.
·
Journal of Clinical Oncology
·
1
PDF
452MO Early experience with azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial
2024
·
E. Pineda
, J.M. Sepúlveda
, et al.
·
Annals of Oncology
·
1
PDF
457P Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
2024
·
J.G. Yaringaño Cerna
, O. Mirallas
, et al.
·
Annals of Oncology
·
1
503MO Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights
2023
·
O. Mirallas
, G. Velilla
, et al.
·
Annals of Oncology
·
1
PDF
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
2023
·
Oriol Mirallas
, Gabriel Velilla
, et al.
·
Journal of Clinical Oncology
·
1
TIP-05 Dose expansion of Debio 0123 (zedoresertib) plus temozolomide in patients with recurrent or progressive glioblastoma
2026
·
Lauren Schaff
, Juan Manuel Sepulveda Sanchez
, et al.
·
Neuro-Oncology
Azeliragon, a RAGE inhibitor, plus temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Final results from a dose-finding phase in the CAN-201 NDG trial.
2026
·
Maria Martinez Garcia
, Manuel Valiente
, et al.
·
Journal of Clinical Oncology
695P Molecular landscape of IDH1/2-mutant gliomas: A Spanish multicentric cohort
2025
·
J.G. Yaringaño Cerna
, O. Mirallas
, et al.
·
Annals of Oncology
Endothelial Activation as a Predictor of Mortality in CD19-Directed CAR-T Therapy (P12-6.001)
2025
·
Jose Maria Cabrera Maqueda
, Elianet Fonseca
, et al.
·
Neurology
P25.03.b Rwd of Idh Mutant Gliomas in Spain, a Retsine - Geino Study
2024
·
M Mazariegos
, R Girones
, et al.
·
Neuro-Oncology
PDF
43P MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
2023
·
D.A. Gomez Puerto
, O. Mirallas
, et al.
·
ESMO Open
PDF
VE21: Robotic fistulectomy and advancement flap for rectal-neobladder fistula
2014
·
R. Ballestero Diego
, M. Gómez
, et al.
·
European Urology Supplements
Show more works
View as search
Works count:
18
Citation count:
20
H-index:
3
I10-index:
Year
Topic
Type